Lu Daopei Medical Group closes RMB500m Series B financing round

Lu Daopei Medical Group, a medical group specializing in hematology, recently announced the completion of a Series B round of financing worth more than 500 million yuan.

Lu Daopei Medical Group, a medical group specializing in hematology, recently announced the completion of a Series B round of financing worth more than 500 million yuan.

The round was led by Singaporean state-owned fund Temasek Holdings, and joined by Investcorp.

Lu Daopei Medical Group was founded in 2001 by Lu Daopei, a distinguished hematologist in China. After nearly 20 years of development, the group now has four hematology hospitals: Hebei Lu Daopei Hematology Hospital, Beijing Lu Daopei Hospital, Beijing Lu Daopei Hematology Hospital and Shanghai Lu Daopei Hospital.

Currently, Lu Daopei Medical Group has become one of the most active hematopoietic stem cell transplantation centers in the world. In 2019, the group has successfully completed 1,081 cases of hematopoietic stem cell transplantation, making it the largest transplantation center in China.

In 2015, Lu Daopei Hospital began working on a clinical trial study of CART for leukemia, and was one of the first centers in the country to conduct this study.

By the end of June 2020, Lu Daopei Hospital has completed 914 clinical trials of CART, making it a leading center in the world.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/25/lu-daopei-medical-group-closes-rmb500m-series-b-financing-round/.

Leave a Reply

Please Login to Comment